Newsroom
  • Press Releases
  • Presentations
Investors
  • Overview
  • Warrant Exercise Inquiries
  • Restricted Stock Inquiries
  • Notice to Stockholders
  • News / Events
  • Company Information
  • Financial Information
  • Stock Data
  • SEC Filings
  • Corporate Governance
Clinical Trial Enrollment
  • Triple-Negative Breast Cancer
  • COVID-19 Mild to Moderate
  • COVID-19 Severe or Critical
Contact

CytoDyn Inc.

  • Home
  • About CytoDyn
    • Meet CytoDyn
  • Our Science
  • Pipeline
    • Overview
    • HIV
    • Cancer
    • GVHD
    • COVID-19
  • Expanded Access
  • Our Team
    • Management Team
    • Board of Directors
  • Careers
    • Now Hiring
  • Scientific Board of Advisors
  • Newsroom
  • Investors
  • Clinical Trial Enrollment
  • Contact
Latest News

FOR THE LATEST DEVELOPING NEWS Click Here

Hospitals Enrolling COVID-19 Severe-to-Critical

Investment Community Webcast on Monday, March 8

Antibody-based strategies in HIV therapy

Dr. Seethamraju’s Presentation at Special isirv-AVG Virtual Conference

Manuscript Accepted by Infectious Diseases Society of America

Into the Looking Glass: Post-Viral Syndrome Post COVID-19

EUA for COVID-19 Vaccines and Treatments in the Philippines

Leronlimab’s Mechanism of Action in COVID-19 Published

Leronlimab role in COVID-19

Experimental Drugs Aim to Treat Long-Haul Covid Patients

Research on Critically Ill COVID-19 Patients Published in Journal of Translational Autoimmunity

Leronlimab and Long-Haulers

Latest Publication Leronlimab Blocks Breast Cancer

CytoDyn Q&A with CEO Nader Pourhassan - January 26

Press Releases

Newsroom

Newsroom

  • Press Releases
  • Presentations

CytoDyn Receives FDA Clearance for Its First Non-HIV Indication for PRO 140

Dec 14, 2015 8:30am EST

Eleven HIV Patients Successfully Reach One Year of Full Virologic Suppression in PRO 140 Monotherapy Phase 2b Extension Study

Dec 01, 2015 8:30am EST

CytoDyn Hires New Senior Vice President of Manufacturing for PRO 140

Nov 24, 2015 6:30am EST

CytoDyn Announces Investment Community Conference Call

Nov 18, 2015 6:30am EST

CytoDyn Injects First Patient in Its Current Phase 3 Study

Oct 22, 2015 6:30am EDT

CytoDyn Files an IND and Full Protocol for Phase 2 Study in GvHD

Oct 20, 2015 6:30am EDT

HIV Patients Successfully Reach One Year of Virologic Suppression in PRO 140 Monotherapy Study

Sep 21, 2015 6:30am EDT

Cytodyn Initiates First Clinical Site for Phase 3 Trial of PRO 140

Aug 05, 2015 4:01pm EDT

CytoDyn Completes Qualification of PRO 140 Material for Phase 3

Jul 29, 2015 6:30am EDT

Evidence of HIV Suppression With PRO 140 Monotherapy Reaching Nearly 11 Months

Jul 15, 2015 6:30am EDT
RSS
  • Prev
    • 1...
    • 24
    • 25
    • 26
    • 27
    • 28
    • 29
    • 30
    • 31
    • 32
    • 33
    Next
    © 2021 CytoDyn Inc. All Rights Reserved.
    • Twitter
    • Facebookj
    Privacy Policy Disclaimer Sitemap